Additional file 4: Figure S3. of Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines

Long-term cisplatin treated UCCs are not enriched for CD90+/CK14+ cells. CD90+, CD44+, and CD49f+ cells in untreated and LTT UCCs as measured by flow cytometry and collectively illustrated in Fig. 5c; representative results from biological triplicates. Unstained cells were used to set gates for positively stained cells. One measurement is shown for each cell line as a representative of biological triplicates. Untr. Ctrl.: Untreated Control; LTT: Long-term cisplatin treatment. (TIF 3017 kb

Additional file 1: of Effects of novel HDAC inhibitors on urothelial carcinoma cells

Figure S1. Lentiviral vector used for HDAC4 overexpression. (JPG 2487 kb

Additional file 3 of Effects of novel HDAC inhibitors on urothelial carcinoma cells

Table S2. Antibodies and conditions used for Western blotting. (DOCX 15 kb

Additional file 2: of Effects of novel HDAC inhibitors on urothelial carcinoma cells

Table S1. Primers used for PCR. (DOCX 21 kb